PAS
AXSM icon

Point72 Asia (Singapore)’s Axsome Therapeutics AXSM Stock Holding History

Point72 Asia (Singapore)’s Portfolio AXSM Stock Details AXSM Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q3 		– Sell
-584
Closed -$47K – 971
2024
Q2 		$47K Buy
+584
New +$43.2K 0.01% 682

Other funds holding AXSM

RI
RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
FFM
Fairmount Funds Management West Conshohocken, Pennsylvania $1.51B AUM 546.08% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.91B AUM 304.52% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return
Macquarie Group
Macquarie Group Sydney, NSW 2000, Australia $23.2B AUM 40.19% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Point72 Asia (Singapore)'s AXSM Position: Q3 2024 in Review

Point72 Asia (Singapore) sold out of Axsome Therapeutics (AXSM) in Q3 2024, closing a stake of 584 shares — an estimated $47K sold.

Point72 Asia (Singapore) first reported a position in AXSM in Q2 2024 and held it in 1 quarter. The position peaked at $47K in Q2 2024. 278 funds tracked by Wall St. Rank hold AXSM as of Q3 2024.

  • Point72 Asia (Singapore) reported no remaining Axsome Therapeutics position as of Q3 2024 after selling out during the quarter.
  • Point72 Asia (Singapore) sold 584 Axsome Therapeutics shares in Q3 2024, an estimated $47K.
  • Point72 Asia (Singapore) first reported a position in Axsome Therapeutics in Q2 2024 and held it in 1 quarter.
  • Point72 Asia (Singapore)'s Axsome Therapeutics position peaked at $47K in Q2 2024.
  • 278 funds tracked by Wall St. Rank held Axsome Therapeutics as of Q3 2024.

Based on Point72 Asia (Singapore)'s 13F filing for Q3 2024, filed 14 Nov 2024.